Oxford BioMedica plc

As of December 31, 2025, Oxford BioMedica plc carries a market capitalization of 74.50B, placing it among publicly traded companies globally. Its enterprise value stands at 79.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Oxford BioMedica plc's next confirmed earnings release is scheduled for April 15, 2027.

As of December 31, 2025, Oxford BioMedica plc has 120.75M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Oxford BioMedica plc maintains a current ratio of 2.20, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Oxford BioMedica plc's stock has declined approximately 10.82% over the past 52 weeks. The 50-day moving average sits at 493.41, while the 200-day moving average is 613.25.

As of December 31, 2025, Oxford BioMedica plc holds 9.69B in cash and equivalents against 14.81B in total debt, resulting in a net debt position of -5.54B. Total book value stands at 9.13B, with working capital of 10.14B providing operational flexibility.

Oxford BioMedica plc's most recent stock split took place on May 30, 2018 with a 50:1 split ratio.